Join us for a 60-minute educational webinar for practising Canadian gastroenterologists on the emerging immune mechanisms under investigation in inflammatory bowel disease (IBD).

Despite an expanded armamentarium, a therapeutic efficacy ceiling persists, with a substantial proportion of patients failing to achieve or sustain remission on any single agent. Additionally, intestinal fibrosis drives stricturing disease and surgery, yet there is no approved anti-fibrotic therapy, no consensus definition of fibrosis, and no validated endpoint.

Participants will examine how these emerging mechanisms are handled in clinical evaluation, addressing target biology that is frequently conflated with established targets due to shared superfamily nomenclature (such as TL1A with anti-TNF therapy) and contrasting the different timeframes required to move mechanisms from gene discovery to clinic (such as the roughly two-decade TL1A arc versus a differently shaped program like miR-124).

Because the agents discussed are pre-NOC and investigational in Canada, this program is delivered as non-promotional disease-state and pathway education, anchored in biology rather than in any single product or development program.